Message :
Required fields
Study quantified coronary plaque changes in patients administered 4 g/day of VASCEPA® (icosapent ethyl) on top of statin therapy
Effect on coronary plaque stabilization reported to be significant at 9 months and sustained at 18 months
DUBLIN, Ireland and BRIDGEWATER, N.J., April 17, 2021 (GLOBE NEWSWIRE) Amarin Corporation plc (NASDAQ:AMRN) today announced that further analyses from the
Effect of Icosapent Ethyl on Progression of Coronary Atherosclerosis in Patients with Elevated Triglycerides on Statin Therapy: EVAPORATE Trial were presented as Late-Breaking Science at European Society of Cardiology (ESC) Preventive Cardiology 2021, the Annual Congress of the European Association of Preventive Cardiology, on April 17, 2021, 3:50 PM CEST (Central European Summer Time) by Andrew Buckler, Founder and CTO of Elucid. As previously reported and published in the
VASCEPA® (Icosapent Ethyl) Reported to Impact Vulnerable Coronary Plaque Features in New
apnews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from apnews.com Daily Mail and Mail on Sunday newspapers.
iShares NASDAQ Biotechnology Index Fund (NASDAQ:IBB), ACADIA Pharmaceuticals Inc (NASDAQ:ACAD) - The Daily Biotech Pulse: Leadership Transition At Amarin, Vaccine Setback For J&J, FDA Nod For Label Expansion of Roche s Asthma Drug
benzinga.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from benzinga.com Daily Mail and Mail on Sunday newspapers.
Amarin Announces CEO Succession Plan
apnews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from apnews.com Daily Mail and Mail on Sunday newspapers.
Author Bio
Alex began writing for the Fool in early 2020 and follows companies in the healthcare sector. Formerly a researcher in the biotech industry, he leverages his science background in his work as a writer and entrepreneur. His interests include exploring his hometown of Boston, traveling in Latin America, and value investing. Follow @alexcarchidi
Would you want to invest in a biotech with a successful product, surging revenue, and barely any debt? And would your answer change if you heard that the stock s price is less than $7 per share?
Hopefully, your answers are yes, and no. For investors eyeing
Amarin Corporation (NASDAQ:AMRN), this isn t an idle exercise. Between the company s hot revenue growth and a deep global market for its newly approved heart disease medication, it has a lot of room to make buyers rich as long as generics and competitors don t eat its lunch.